SciVision plans to offer 0% three-year convertible bonds

By Mary-Katherine Stinson

Lexington, Ky., May 3 – SciVision Biotech Inc.’s board of directors announced its intention to issue a second domestic conversion of 0% three-year convertible corporate bonds.

The issue will be capped at NT$400 million, according to a company announcement.

The bonds will have a face value per bond of NT$100,000 and will be issued at par.

President Securities Corp. is the underwriter or agent.

The trustee is Cathay United Bank Co. Ltd.

Horizon Securities Co., Ltd. is the principal paying agent.

Proceeds will be used to repay bank loans and increase working capital.

Based in Kaohsiung, Taiwan, SciVision is a manufacturer of medical-grade hyaluronic acid products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.